General Flashcards

1
Q

What is the major disadvantage of clinical therapy involving drugs that act on ANS?

A

Lack of specificity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Parasympathetics control…

A

cardiac and smooth muscle
gland cells
nerve terminals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Parasympathetic presynaptic

A

nicotinic cholinergic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Parasympathetic postsynaptic

A

muscarinic cholinergic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Sympathetic (sweat glands) postsynaptic

A

muscarinic cholinergic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

postsynaptic motor neurons

A

nicotinic cholinergic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

sympathetic (cardiac and smooth muscle, gland cells, nerve terminals) postsynaptic motor neurons

A

adrenergic (alpha and beta)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Sympathetic (renal vascular smooth muscle) postsynaptic motor neuron

A

dopamine receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Adrenal medulla

A

nicotinic cholinergic receptor

releases Epi, NE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cholinergic receptor types

A

muscarinic

Nicotinic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

muscarinic subtypes

A

M1, M3, M5…Gq coupled

M2, M4….Gi coupled

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Gq coupled muscarinic receptors

A

M1
M3
M5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Gi coupled muscarinic receptors

A

M2

M4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Nicotinic subtypes

A

Nm (neuromuscular/muscle type)

Nn (neuronal, or ganglion type)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Adrenergic subtypes

A

alpha 1, alpha 2

beta 1, beta 2, [beta 3]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dopamine receptor subtypes

A

D1-D5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Other receptors

A

for NANC transmitters

  • -NO
  • -vasoactive intestinal peptide
  • -neuropeptide Y
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

5 key features of neurotransmitter function that provide targets for drug therapy?

A
Synthesis
Storage
Release
Reuptake
Degredation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

If Synthesis and Storage blocked…

A

usually rate-limiting steps, so…

produce long-term effects, but not immediately effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

If release blocked…

A

Rapid action and effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

If reuptake blocked…

A

Increased synaptic neurotransmitter concentrations (selective or non-selective)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

If metabolism blocked…

A

reversible or irreversible:

increases transmitter levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

If recognition is blocked…

A

Receptor antagonists and agonists…high specificity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Sympathomimetic

A

mimicks… effects of impulses conveyed by adrenergic postganglionic fibers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Sympatholytic
anti adrenergic...
26
Fundamental difference b/w methods of inactivation of acetylcholine vs. norepinephrine
acetylcholine-->degraded | NE-->reuptake
27
hemicholiniums
EXPERIMENTAL, NOT CLINICAL block CHT (that transports Na and choline in)
28
Vesamicol
EXPERIMENTAL,, NOT CLINICAL blocks VAT
29
Cotransmitters
modulation (enhance or diminish cholinergic activity)
30
Cholinergic Autoreceptors
ACh activates the receptors, but this inhibits further release of ACh
31
Blocking the Ca channels...
inhibits sweating?
32
Metabotropic
function through secondary messanger system Muscarinic receptors
33
Ionotropic
ion channels nicotinic
34
M1, M3, M5
Metabotropic Gq -->PLC-->IP3-->INCREASES INTRACELLULAR CALCIUM!!!
35
M2, M4
Metabotropic Gi blocks adenylate cyclase from making cAMP inhibitory response opens K channels (GiRK)
36
nicotinic receptors
ionotropic increase intracellular Calcium, Na, PKC amplifies effect
37
If drug not susceptible to cholineterase, then...
improves longevity of drug | i.e. carbachol chloride and bethanechol chloride
38
metyrosine
inhibits tyrosine hydroxylase | tyrosine synthesis to dopamine
39
Reserpine
Blocks VMAT
40
Cocaine, tricylic antidepressants
``` block NET (prevents neurotransmitters from being broken down/ repackaged) ```
41
What process is critical for catecholamine neurotransmission?
reuptake!
42
Phenylephrine Methoxamine (receptor affinity)
alpha agonists | alpha1>alpha2>>>>>>>>>>>beta
43
Clonidine methylmorepinephrine (receptor affinity)
alpha agonists | alpha2>alpha1>>>>>>>>>>>>beta
44
Norepinephrine (receptor affinity)
mixed alpha and beta agonists alpha1=alpha2 beta1>>beta2
45
epinephrine (receptor affinity)
mixed alpha and beta agonists alpha1=alpha2 beta1=beta2
46
Does norepinephrine widen pulse pressure?
no
47
Why does epiniephrine widen the pulse pressure?
b/c of beta 2 receptors
48
dobutamine (receptor affinity)
beta agonists beta1>beta2>>>>>>>alpha
49
isoproterenol
beta agonist beta1=beta2>>>>>>alpha
50
Albuterol, terbutaline metaproterenol (receptor affinity)
beta agonists beta2>>beta1>>>>>>alpha
51
dopamine
dopamine agonist | d1=d2>>beta>>alpha
52
Fenoldopam
dopamine agonist | D1>>D2
53
ACh and muscarinic receptors have inhibitory effect on...
adrenergic and enteric neuron terminals
54
NE and alpha2 receptors have inhibitory effect on...
adrenergic neuron terminals
55
alpha1 adrenergic receptors
metabotrophic Gq GDP-->GTP-->phospholipase C-->IP3-->Calcium!!!-->protein kinase activation
56
beta catechloamine receptors
Metabotrophic stimulatory Gs -->GDP-->GTP-->adenylate cyclase-->cAMP-->protein kinease-->enzyme-PO4-->biologic effect
57
alpha2 adrenergic receptors
Metabotrophic inhibitory Gi -->GDP-->GTP-->BLOCKS adenylate cyclase!!!
58
beta2 agonist effect on smooth muscle
relaxes | asthma treatment!
59
Ca channel blockers effect on smooth muscle
relaxes
60
COMT | catechol-O-methyl transferase
drug target | involved in catecholamine degredation/ synthesis
61
MAO | monoamine oxidase
drug target | involved in catecholamine degredation/ synthesis
62
Pheochromocytma
chromaffin tumors typically arising in adrenal glands secreting excessive catecholamines
63
how to diagnose pheochromocytoma
look for urinary catecholamine metabolites metanephrine and vanillylmandelic acid
64
L-DOPA
dopamine precursor can be used in treatment of Parkinson's --b/c can cross blood brain barrier (unlike dopamine) --give w/ inhibitors in the periphery (where we don't want its effects)
65
MAOA inhibitors
block tyramine metabolism - ->increased tyramine in blood circulation - ->cheese rxn!! (must avoid many many foods)
66
Desensitization process
1. G-protein coupled receptor 2. drug ligand binds (dynamics of binding somewhat different than endogenous ligand) 3. duration and extent of drug binding causes... 4. accumulation of BETA-ARRESTINS 5. Receptors taken down from cell surface into cell in vesicles 6. fewer receptors means "less bang for the buck"
67
beta-arrestins
proteins involved in desensitization
68
Tachyphylaxis
"loss of activity" in relatively short space of time (tolerance to drug b/c of chronic, constant administration) - -changes of metabolism - -clonal expansion of resistant tumor - -ect
69
what can stimulate glycogenolysis and gluconeogenesis in liver and why?
alpha1 and beta2 receptors in response to hypoglycemia
70
Why are beta blockers a problem for diabetics?
--nonselective beta blockers delay recovery from hypoglycemia in type 1 diabetics --can interfere w/ counter-regulatory effects by blunting perception of hypoglycemic symptoms (tremor, tachycardia, nervousness) Beta1-selective antagonist is preferred!
71
Pancreatic beta cells and insulin... | alpha2 activation significantly...
decreases insulin secretion
72
Pancreatic beta cells and insulin... | beta-2 activation...
inreases insulin secretion
73
The target tissue and insulin sensitivity... | beta receptor activation...
increases receptor sensitivity
74
The target tissue and insulin sensitivity... | beta-blockers
decrease insulin sensitivity
75
The target tissue and insulin sensitivity... | beta-blockers (vasodilating...3rd generation... drugs
increase insulin sensitivity in pts w/ insulin resistance
76
Hormone sensitive lipase... | non-selective beta-blockers...
lower HDL cholesterol and increase TGs | little effect on LDL and total cholesterol
77
alpha1 receptors involved in...
vascular tone urethral tone ejactulation process maintaining contractile state of penile arteries
78
alpha1 receptor blockage can result in...
orthostatic hypotension relieved symptoms of BPH sexual dysfunction persistent priapism
79
Why, when alpha1-receptors blocked by promethazine, does the blood pressure drop, but the heart rate is still able to increase?
the receptors blocked are dominant in vessels but not in heart
80
peripheral anticholinergic effects
no innervation of blood vessels, but there are still receptors xerostomia caused by ACh inhibition in salivary glands treatment of hypersalivation blurred vision; cycloplegia; mydriasis constipation (b/c inhibition of GI smooth muscle) IBS urinary retention secondary to decreased muscle tone muscarinic agonist or AChE inhibitor
81
NO
vasodilator | GDP-->cGMP-->smooth muscle relaxation
82
Sidenafil (viagra)
vasodilator inhibits cGMP break down to GMP -->prolonged smooth muscle relaxation
83
what can blocking cholinergic and GABAergic pathways connected in hippocampus and basal forebrain complex do?
make us sleepy
84
Drugs w/ anticholinergic activity
1st generation antihistamines antidepressants etc.
85
Sumpathetic NS drugs
``` alpha-blockers beta-blockers centrally-acting drugs transmitter depleting drugs ganglionic blocking drugs ```
86
cardiotonic drugs
beta-agonists alpha-agonists muscarinic antagonists